<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03473236</url>
  </required_header>
  <id_info>
    <org_study_id>4004002</org_study_id>
    <nct_id>NCT03473236</nct_id>
  </id_info>
  <brief_title>Phase 1A Safety Trial of Inhaled PK10571 (GB002)</brief_title>
  <official_title>A Phase 1A Single Ascending Dose and Multiple Ascending Dose Double-Blind, Placebo-Controlled, Randomized Trial of Oral Inhalation PK10571 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pulmokine Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gossamer Bio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1A randomized double blind placebo controlled single ascending dose and
      multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, single-center, randomized, double-blind, placebo-controlled,
      two-part study in healthy adult males and females of non-childbearing potential.
      &quot;Double-Blind&quot; means neither the study subject nor the investigator knows if PK10571 or
      placebo is being given. &quot;Placebo&quot; means a capsule filled with a powder that does not contain
      the active drug, PK10571. Because the safety profile of PK10571 in humans is unknown and this
      is the first clinical study to assess PK10571 in humans, a single-ascending dose design will
      be used in Part A of the study going from a low dose to higher doses based on safety. Part B
      will be a multiple-ascending dose design to be run only after review of safety and
      measurement of drug levels in the blood from Part A.

      In the single ascending dose study (Part A) up to five doses may be given to different groups
      of study subjects based on safety and measurement of drug levels in the blood. Subjects will
      be randomized into one dose cohort to receive either PK10571 or placebo. Within each cohort,
      6 subjects will receive active drug and 2 subjects will receive placebo.

      In the multiple ascending dose study (Part B), up to three doses of PK10571 will be tested.
      The daily dose will be administered daily for 7 days with close clinical monitoring. The dose
      for the first cohort of Part B will be determined by review of the safety and drug levels
      from Part A by the Safety Review Committee. The dose interval for the first cohort of Part B
      (i.e., once daily, twice daily, or up to three times daily) will be determined by review of
      the safety and drug levels in the blood from Part A by the Safety Review committee.
      Subsequent doses and dosing intervals will be determined by review of the safety and drug
      levels from the prior cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A serious AE (SAE) is one that, in the view of either the investigator or Sponsor, results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. A TEAE is defined as any AE that has an onset on or after the first dose of study drug and before the end of study/end of treatment (EoS/ET) visit, or any pre-existing condition that has worsened in severity on or after the first dose of study drug and before the EoS/ET visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vital Sign Findings Reported as TEAEs</measure>
    <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
    <description>Vital signs evaluated included blood pressure, pulse oximetry, respiratory rate, and temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Findings in Physical Examinations</measure>
    <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
    <description>Physical examination assessments included: physical exam for general appearance; head, ears, eyes, nose and throat; thyroid; lymph nodes; back and neck; heart; chest; lungs; abdomen; skin; and extremities, musculoskeletal and neurological.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in ECG Data (Overall Interpretation)</measure>
    <time_frame>SAD: Baseline, Day 2, 24 hours; MAD: Baseline, Day 8, 24 hours</time_frame>
    <description>12-lead electrocardiograms (ECG) assessments included heart rate, PR interval, QRS duration, QT interval, QTc interval, QTc interval corrected using Bazett's formula (QTcB), QTc interval corrected using Fridericia's formula (QTcF), RR interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormal Findings in Pulmonary Function Tests</measure>
    <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
    <description>Pulmonary function tests included forced vital capacity; forced expiratory volume in 1 second (FEV1); forced expiratory flow 25%-75% (FEF25-75); percent predicted forced vital capacity; percent predicted FEV1; and percent predicted FEF25-75.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Analysis of Inhaled GB002: Maximum Concentration (Cmax), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Time to Cmax (Tmax), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Last Quantifiable Concentration (AUClast), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Infinity (AUCinf), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Apparent Terminal Elimination Half-Life (t1/2), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance (CL/F), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
    <description>CL/F is based on nominal (scheduled) dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Apparent Volume of Distribution (Vz/F), SAD</measure>
    <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
    <description>Vz/F is based on nominal (scheduled) dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Cmax After Dose 1, MAD</measure>
    <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Tmax After Dose 1, MAD</measure>
    <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Area Under the Curve From Time Zero to 24 Hours Postdose (AUC0-24), MAD</measure>
    <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Trough Plasma Concentration (Ctrough), MAD</measure>
    <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Accumulation Ratio (Rac) for Cmax After Dose 1, MAD</measure>
    <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Rac for AUC0-24, MAD</measure>
    <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Rac for Ctrough, MAD</measure>
    <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: t1/2, MAD</measure>
    <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance at Steady-State (CLss/F), MAD</measure>
    <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Analysis of Inhaled GB002: Vz/F, MAD</measure>
    <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Change From Baseline in White Blood Cell Count</measure>
    <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
    <description>Measurement of white blood cell count</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Hemoglobin</measure>
    <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
    <description>Measurement of hemoglobin</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Kidney Function Parameters</measure>
    <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
    <description>Measurement of blood urea nitrogen (BUN) and creatinine.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Liver Function Parameters</measure>
    <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
    <description>Measurement of liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]).</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB002</intervention_name>
    <description>Inhaled GB002</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_label>Cohort 5A</arm_group_label>
    <other_name>PK10571</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Generic Dry Powder Inhaler</intervention_name>
    <description>dry powder inhaler used for inhalation of active drug or placebo</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_label>Cohort 5A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo</description>
    <arm_group_label>Cohort 1A</arm_group_label>
    <arm_group_label>Cohort 1B</arm_group_label>
    <arm_group_label>Cohort 2A</arm_group_label>
    <arm_group_label>Cohort 2B</arm_group_label>
    <arm_group_label>Cohort 3A</arm_group_label>
    <arm_group_label>Cohort 3B</arm_group_label>
    <arm_group_label>Cohort 4A</arm_group_label>
    <arm_group_label>Cohort 5A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females (if unable to become pregnant)

          -  Age 18-55

          -  Body mass index (BMI) 18-32 kg/m^2 and minimum weight of 50 kg (110 lbs)

          -  Non-smoker

          -  Ability to give informed consent

          -  Ability to remain in study unit for duration of study and return for outpatient visits

          -  Ability to use dry powder inhaler (DPI) effectively

        (See full protocol for additional details.)

        Exclusion Criteria:

          -  Hospitalization within the 6 months prior to the first dose of study treatment

          -  History or presence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,
             neurologic, oncologic, or psychiatric disease or any other condition that, in the
             opinion of the Investigator, would jeopardize the safety of the subject or the
             validity of the study results

          -  History or presence of active lung disease (i.e., asthma, chronic obstructive
             pulmonary disease [COPD], pulmonary fibrosis, hemoptysis, bronchiectasis) or prior
             intubation

          -  Currently uses an inhaler

          -  History or presence of heart disease (i.e., prior myocardial infarction [MI], coronary
             artery disease, heart failure, hypertension, pulmonary hypertension, valve disease,
             atrial fibrillation, other arrhythmia, or prolonged QT syndrome)

          -  History or presence of cancer (with the exception of basal cell skin cancer that has
             been effectively treated)

          -  History of diabetes mellitus

          -  History of thyroid disease other than hypothyroidism control with levothyroxine and
             documented normal thyroid-stimulating hormone (TSH)

          -  History of tuberculosis, Lyme disease, or other chronic or opportunistic infection.

          -  History of positive purified protein derivative (PPD) skin test, or positive PPD test
             at screening

          -  Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human
             immunodeficiency virus (HIV) at screening or has been previously treated for hepatitis
             B, hepatitis C, or HIV infection

          -  History of smoking within the past 15 years

          -  Is a female with a positive pregnancy test result, or who has the ability to become
             pregnant, or who is lactating

          -  Has forced expiratory volume in 1 second (FEV1) less than 80% predicted, forced vital
             capacity (FVC) ˂80% predicted, or resting oxygen saturation less than 97% on room air
             at screening or baseline

          -  Upper respiratory infection within the 3 months prior to the first dose of medication

          -  History of major bleeding or major surgical procedure of any type within 6 months
             prior to the first dose of medication

          -  History of minor bleeding disorders such as epistaxis, rectal bleeding (spots of blood
             on toilet paper), and gingival bleeding within 3 months before the study treatment

          -  History of bleeding disorder or coagulopathy

          -  Females with history of dysfunctional uterine bleeding, including history of
             menorrhagia or metrorrhagia, unless subject has had a hysterectomy.

          -  History of GI bleed

          -  Has used any over-the-counter (OTC) medication, nutritional or dietary supplements,
             herbal preparations, or vitamins within 7 days prior to the first dose of medication

          -  Has used any antiplatelet agents such as acetylsalicylic acid (ASA), nonsteroidal
             anti-inflammatory drugs (NSAIDs), clopidogrel (or similar agent) or anti-coagulants
             within 7 days prior to the first dose of medication

          -  Has used any prescription medication, except female hormonal replacement therapy,
             within 14 days prior to the first dose of study medication

          -  Has been treated with any known drugs that are moderate or strong inhibitors/inducers
             of CYP enzymes such as barbiturates, phenothiazines, cimetidine, carbamazepine, etc.,
             within 30 days prior to the first dose of study medication and that in the
             Investigator's judgment may impact subject safety or the validity of the study results

          -  History of peripheral vascular disease

          -  History of autoimmune or collagen vascular disease

          -  History of sleep apnea

          -  History of clinically significant allergy to medications

          -  History of anaphylaxis

          -  History of liver disease

          -  History of alcohol or drug abuse

          -  Prolonged QTc on 12-lead ECG (i.e., QTc corrected using Fridericia's formula [QTcF]
             ˃450 msec), PR &gt;210 msec, or QRS &gt;110 msec at screening.

          -  Evidence of prior MI on ECG; presence of atrial fibrillation on ECG; presence of
             pre-excitation, 2nd or 3rd degree heart block, or abnormal waveform morphology that
             would preclude accurate measurement of the QT interval duration or other clinically
             significant abnormalities

          -  Chest x-ray reveals presence of infiltrate or other abnormality (mass, granuloma,
             fibrosis, pulmonary thickening, pleural effusion, pulmonary edema, wide mediastinum,
             cardiomegaly, or clinically significant increased interstitial markings)

          -  History of neurologic disorder (i.e., multiple sclerosis, amyotrophic lateral
             sclerosis [ALS], cerebrovascular accident [CVA], transient ischemic attach [TIA])

          -  History of deep vein thrombosis or pulmonary embolus

          -  History of clotting disorder

          -  History of mental illness requiring drug treatment or hospitalization

          -  History of renal failure or proteinuria (defined as 1+ proteinuria: ≥75 mg/dL on
             isolated urinalysis)

          -  Test results greater than the upper limit of normal (ULN) for AST, ALT, or total
             bilirubin

          -  Out of range results on the following coagulation tests: INR, prothrombin time (PT),
             or partial thromboplastin time (PTT)

          -  Total cholesterol &gt;250 mg/dL or triglycerides &gt;300 mg/dL at screening (based on
             fasting lipid profile)

          -  Estimated creatinine clearance less than 60 mL/min

          -  Hemoglobin at screening of &lt;11.5 g/dl (if female subject) or &lt;12.5 g/dl (if male
             subject)

          -  Has a clinically significant abnormal finding on the physical exam, medical history,
             electrocardiogram (ECG), or clinical laboratory results at screening. Note: Subjects
             with abnormal laboratory results not specifically excluded by this protocol may be
             enrolled if the Investigator deems the out-of-range values as not clinically
             significant

          -  History of treatment with a kinase inhibitor

          -  Has been on a significantly abnormal diet during the 4 weeks preceding the first dose
             of study medication

          -  Has donated blood or plasma within 30 days prior to the first dose of study medication

          -  Has participated in another clinical trial (randomized subjects only) within 30 days
             prior to the first dose of study medication

          -  Has a positive urine screen for drugs of abuse (amphetamines, barbiturates,
             benzodiazepines, cocaine, cannabinoids, opiates) or cotinine

          -  Vital signs (measured sitting after 3 minutes rest) at screening that are not within
             the following ranges (inclusive): heart rate: 40-100 beats per minute [bpm]; systolic
             blood pressure (BP): 90-145 mmHg; diastolic BP: 50-95 mmHg. Out-of-range vital signs
             may be repeated once. Blood pressure will be measured in both arms at screening, with
             a 3-minute rest between each measurement. Predose vital signs will be assessed by the
             Principal Investigator or designee (e.g., a medically qualified sub-investigator)
             prior to study drug administration. The Principal Investigator or designee will verify
             the eligibility of each subject with out-of-range vital signs and document approval
             prior to dosing

          -  Significant difference (i.e., greater than 15 mmHg) between the systolic blood
             pressure in each arm at screening

          -  History of lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phase 1 Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <results_first_submitted>November 19, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03473236/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03473236/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SAD PK10571 (GB002) Placebo QD</title>
          <description>A placebo single ascending dose (SAD) inhaled once a day (QD) over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P2">
          <title>SAD GB002 3.75 mg QD</title>
          <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P3">
          <title>SAD GB002 7.5 mg QD</title>
          <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P4">
          <title>SAD GB002 15 mg QD</title>
          <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P5">
          <title>SAD GB002 30 mg QD</title>
          <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P6">
          <title>SAD GB002 48 mg QD</title>
          <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="P7">
          <title>MAD GB002 Placebo BID/TID</title>
          <description>A placebo multiple ascending dose (MAD) inhaled either twice daily (BID) or thrice daily (TID) over 35 days in healthy volunteers</description>
        </group>
        <group group_id="P8">
          <title>MAD GB002 18 mg BID</title>
          <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="P9">
          <title>MAD GB002 24 mg TID</title>
          <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="P10">
          <title>MAD GB002 48 mg TID</title>
          <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SAD GB002 Placebo QD</title>
          <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B2">
          <title>SAD GB002 3.75 mg QD</title>
          <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B3">
          <title>SAD GB002 7.5 mg QD</title>
          <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B4">
          <title>SAD GB002 15 mg QD</title>
          <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B5">
          <title>SAD GB002 30 mg QD</title>
          <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B6">
          <title>SAD GB002 48 mg QD</title>
          <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="B7">
          <title>MAD GB002 Placebo BID/TID</title>
          <description>A placebo MAD inhaled either BID or TID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="B8">
          <title>MAD GB002 18 mg BID</title>
          <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="B9">
          <title>MAD GB002 24 mg TID</title>
          <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="B10">
          <title>MAD GB002 48 mg TID</title>
          <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="7"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="7.72"/>
                    <measurement group_id="B2" value="39.0" spread="7.54"/>
                    <measurement group_id="B3" value="36.8" spread="10.34"/>
                    <measurement group_id="B4" value="38.5" spread="8.78"/>
                    <measurement group_id="B5" value="39.5" spread="6.28"/>
                    <measurement group_id="B6" value="35.4" spread="9.59"/>
                    <measurement group_id="B7" value="33.3" spread="11.31"/>
                    <measurement group_id="B8" value="49.3" spread="4.13"/>
                    <measurement group_id="B9" value="31.7" spread="8.83"/>
                    <measurement group_id="B10" value="41.0" spread="6.10"/>
                    <measurement group_id="B11" value="38.8" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.52" spread="12.156"/>
                    <measurement group_id="B2" value="165.82" spread="10.699"/>
                    <measurement group_id="B3" value="171.03" spread="14.785"/>
                    <measurement group_id="B4" value="169.30" spread="6.427"/>
                    <measurement group_id="B5" value="172.58" spread="16.351"/>
                    <measurement group_id="B6" value="165.84" spread="11.783"/>
                    <measurement group_id="B7" value="169.22" spread="11.468"/>
                    <measurement group_id="B8" value="162.27" spread="8.190"/>
                    <measurement group_id="B9" value="164.43" spread="9.351"/>
                    <measurement group_id="B10" value="167.45" spread="10.418"/>
                    <measurement group_id="B11" value="168.23" spread="11.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bodyweight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.55" spread="8.023"/>
                    <measurement group_id="B2" value="77.77" spread="15.075"/>
                    <measurement group_id="B3" value="70.37" spread="16.170"/>
                    <measurement group_id="B4" value="76.33" spread="8.091"/>
                    <measurement group_id="B5" value="90.68" spread="18.925"/>
                    <measurement group_id="B6" value="70.37" spread="6.307"/>
                    <measurement group_id="B7" value="81.27" spread="15.944"/>
                    <measurement group_id="B8" value="74.58" spread="12.449"/>
                    <measurement group_id="B9" value="72.24" spread="8.247"/>
                    <measurement group_id="B10" value="65.45" spread="12.565"/>
                    <measurement group_id="B11" value="75.95" spread="13.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.85" spread="2.804"/>
                    <measurement group_id="B2" value="28.07" spread="3.195"/>
                    <measurement group_id="B3" value="23.88" spread="3.407"/>
                    <measurement group_id="B4" value="26.60" spread="1.932"/>
                    <measurement group_id="B5" value="30.18" spread="1.520"/>
                    <measurement group_id="B6" value="25.86" spread="3.574"/>
                    <measurement group_id="B7" value="28.25" spread="3.384"/>
                    <measurement group_id="B8" value="28.18" spread="2.712"/>
                    <measurement group_id="B9" value="26.89" spread="3.609"/>
                    <measurement group_id="B10" value="23.20" spread="2.589"/>
                    <measurement group_id="B11" value="26.79" spread="3.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A serious AE (SAE) is one that, in the view of either the investigator or Sponsor, results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. A TEAE is defined as any AE that has an onset on or after the first dose of study drug and before the end of study/end of treatment (EoS/ET) visit, or any pre-existing condition that has worsened in severity on or after the first dose of study drug and before the EoS/ET visit.</description>
        <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
        <population>Safety Population: all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A serious AE (SAE) is one that, in the view of either the investigator or Sponsor, results in any of the following outcomes: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. A TEAE is defined as any AE that has an onset on or after the first dose of study drug and before the end of study/end of treatment (EoS/ET) visit, or any pre-existing condition that has worsened in severity on or after the first dose of study drug and before the EoS/ET visit.</description>
          <population>Safety Population: all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Treatment Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Early Termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vital Sign Findings Reported as TEAEs</title>
        <description>Vital signs evaluated included blood pressure, pulse oximetry, respiratory rate, and temperature.</description>
        <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
        <population>Safety Population: all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Findings Reported as TEAEs</title>
          <description>Vital signs evaluated included blood pressure, pulse oximetry, respiratory rate, and temperature.</description>
          <population>Safety Population: all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Findings in Physical Examinations</title>
        <description>Physical examination assessments included: physical exam for general appearance; head, ears, eyes, nose and throat; thyroid; lymph nodes; back and neck; heart; chest; lungs; abdomen; skin; and extremities, musculoskeletal and neurological.</description>
        <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
        <population>Safety Population: all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Findings in Physical Examinations</title>
          <description>Physical examination assessments included: physical exam for general appearance; head, ears, eyes, nose and throat; thyroid; lymph nodes; back and neck; heart; chest; lungs; abdomen; skin; and extremities, musculoskeletal and neurological.</description>
          <population>Safety Population: all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes From Baseline in ECG Data (Overall Interpretation)</title>
        <description>12-lead electrocardiograms (ECG) assessments included heart rate, PR interval, QRS duration, QT interval, QTc interval, QTc interval corrected using Bazett's formula (QTcB), QTc interval corrected using Fridericia's formula (QTcF), RR interval.</description>
        <time_frame>SAD: Baseline, Day 2, 24 hours; MAD: Baseline, Day 8, 24 hours</time_frame>
        <population>Safety Population: all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes From Baseline in ECG Data (Overall Interpretation)</title>
          <description>12-lead electrocardiograms (ECG) assessments included heart rate, PR interval, QRS duration, QT interval, QTc interval, QTc interval corrected using Bazett's formula (QTcB), QTc interval corrected using Fridericia's formula (QTcF), RR interval.</description>
          <population>Safety Population: all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Abnormal Findings in Pulmonary Function Tests</title>
        <description>Pulmonary function tests included forced vital capacity; forced expiratory volume in 1 second (FEV1); forced expiratory flow 25%-75% (FEF25-75); percent predicted forced vital capacity; percent predicted FEV1; and percent predicted FEF25-75.</description>
        <time_frame>SAD: from first dose of study drug to 11 days, MAD: from first dose of study drug to 35 days</time_frame>
        <population>Safety Population: all participants who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Abnormal Findings in Pulmonary Function Tests</title>
          <description>Pulmonary function tests included forced vital capacity; forced expiratory volume in 1 second (FEV1); forced expiratory flow 25%-75% (FEF25-75); percent predicted forced vital capacity; percent predicted FEV1; and percent predicted FEF25-75.</description>
          <population>Safety Population: all participants who received any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Analysis of Inhaled GB002: Maximum Concentration (Cmax), SAD</title>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Analysis of Inhaled GB002: Maximum Concentration (Cmax), SAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="41.32"/>
                    <measurement group_id="O2" value="51.7" spread="36.88"/>
                    <measurement group_id="O3" value="161" spread="33.12"/>
                    <measurement group_id="O4" value="184" spread="78.39"/>
                    <measurement group_id="O5" value="377" spread="32.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Time to Cmax (Tmax), SAD</title>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Time to Cmax (Tmax), SAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                    <measurement group_id="O2" value="0.0500" lower_limit="0.0500" upper_limit="0.183"/>
                    <measurement group_id="O3" value="0.0500" lower_limit="0.0500" upper_limit="0.0500"/>
                    <measurement group_id="O4" value="0.0500" lower_limit="0.0500" upper_limit="0.0500"/>
                    <measurement group_id="O5" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Last Quantifiable Concentration (AUClast), SAD</title>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Last Quantifiable Concentration (AUClast), SAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="35.19"/>
                    <measurement group_id="O2" value="60.6" spread="23.01"/>
                    <measurement group_id="O3" value="147" spread="19.51"/>
                    <measurement group_id="O4" value="214" spread="28.55"/>
                    <measurement group_id="O5" value="423" spread="44.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Infinity (AUCinf), SAD</title>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time 0 Hours to Infinity (AUCinf), SAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="34.50"/>
                    <measurement group_id="O2" value="60.9" spread="22.90"/>
                    <measurement group_id="O3" value="147" spread="19.43"/>
                    <measurement group_id="O4" value="215" spread="28.48"/>
                    <measurement group_id="O5" value="423" spread="44.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Apparent Terminal Elimination Half-Life (t1/2), SAD</title>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Apparent Terminal Elimination Half-Life (t1/2), SAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="25.72"/>
                    <measurement group_id="O2" value="3.08" spread="28.54"/>
                    <measurement group_id="O3" value="3.32" spread="12.68"/>
                    <measurement group_id="O4" value="4.41" spread="23.00"/>
                    <measurement group_id="O5" value="4.16" spread="20.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance (CL/F), SAD</title>
        <description>CL/F is based on nominal (scheduled) dose.</description>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance (CL/F), SAD</title>
          <description>CL/F is based on nominal (scheduled) dose.</description>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="34.50"/>
                    <measurement group_id="O2" value="123" spread="22.90"/>
                    <measurement group_id="O3" value="102" spread="19.43"/>
                    <measurement group_id="O4" value="140" spread="28.48"/>
                    <measurement group_id="O5" value="113" spread="44.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Apparent Volume of Distribution (Vz/F), SAD</title>
        <description>Vz/F is based on nominal (scheduled) dose.</description>
        <time_frame>0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Apparent Volume of Distribution (Vz/F), SAD</title>
          <description>Vz/F is based on nominal (scheduled) dose.</description>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650" spread="25.86"/>
                    <measurement group_id="O2" value="548" spread="24.12"/>
                    <measurement group_id="O3" value="489" spread="18.33"/>
                    <measurement group_id="O4" value="889" spread="32.24"/>
                    <measurement group_id="O5" value="681" spread="44.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Cmax After Dose 1, MAD</title>
        <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Cmax After Dose 1, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" spread="35.4"/>
                    <measurement group_id="O2" value="229" spread="55.1"/>
                    <measurement group_id="O3" value="571" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193" spread="27.0"/>
                    <measurement group_id="O2" value="246" spread="49.0"/>
                    <measurement group_id="O3" value="528" spread="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Tmax After Dose 1, MAD</title>
        <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Tmax After Dose 1, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                    <measurement group_id="O2" value="0.0833" lower_limit="0.0833" upper_limit="0.117"/>
                    <measurement group_id="O3" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                    <measurement group_id="O2" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                    <measurement group_id="O3" value="0.0833" lower_limit="0.0833" upper_limit="0.0833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time Zero to 24 Hours Postdose (AUC0-24), MAD</title>
        <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Area Under the Curve From Time Zero to 24 Hours Postdose (AUC0-24), MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355" spread="25.9"/>
                    <measurement group_id="O2" value="870" spread="38.1"/>
                    <measurement group_id="O3" value="1690" spread="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" spread="13.6"/>
                    <measurement group_id="O2" value="827" spread="20.2"/>
                    <measurement group_id="O3" value="1870" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Trough Plasma Concentration (Ctrough), MAD</title>
        <time_frame>Days 1 and 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Trough Plasma Concentration (Ctrough), MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="65.4"/>
                    <measurement group_id="O2" value="2.60" spread="55.3"/>
                    <measurement group_id="O3" value="3.83" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="51.9"/>
                    <measurement group_id="O2" value="2.54" spread="26.0"/>
                    <measurement group_id="O3" value="4.29" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Accumulation Ratio (Rac) for Cmax After Dose 1, MAD</title>
        <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Accumulation Ratio (Rac) for Cmax After Dose 1, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="27.3"/>
                    <measurement group_id="O2" value="1.13" spread="24.9"/>
                    <measurement group_id="O3" value="0.925" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Rac for AUC0-24, MAD</title>
        <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Rac for AUC0-24, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="25.6"/>
                    <measurement group_id="O2" value="0.985" spread="23.5"/>
                    <measurement group_id="O3" value="1.11" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Rac for Ctrough, MAD</title>
        <time_frame>Days 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Rac for Ctrough, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="27.1"/>
                    <measurement group_id="O2" value="0.844" spread="41.0"/>
                    <measurement group_id="O3" value="1.12" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: t1/2, MAD</title>
        <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: t1/2, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="7.04"/>
                    <measurement group_id="O2" value="4.68" spread="18.2"/>
                    <measurement group_id="O3" value="5.75" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance at Steady-State (CLss/F), MAD</title>
        <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Apparent Total Plasma Clearance at Steady-State (CLss/F), MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread="13.55"/>
                    <measurement group_id="O2" value="87.1" spread="20.17"/>
                    <measurement group_id="O3" value="76.9" spread="42.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Analysis of Inhaled GB002: Vz/F, MAD</title>
        <time_frame>Day 7: 0 hour (predose), and then at 3, 10, 20, 30, 40 minutes, and 1, 2, 4, 8, 12, 24, 36, and 48 hours after the start of study treatment administration</time_frame>
        <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>PK Analysis of Inhaled GB002: Vz/F, MAD</title>
          <population>PK population: all participants who received active study drug and had at least one quantifiable postdose concentration.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495" spread="9.46"/>
                    <measurement group_id="O2" value="588" spread="18.55"/>
                    <measurement group_id="O3" value="604" spread="29.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in White Blood Cell Count</title>
        <description>Measurement of white blood cell count</description>
        <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in White Blood Cell Count</title>
          <description>Measurement of white blood cell count</description>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.212"/>
                    <measurement group_id="O2" value="-0.07" spread="1.417"/>
                    <measurement group_id="O3" value="-0.25" spread="1.334"/>
                    <measurement group_id="O4" value="-0.93" spread="1.694"/>
                    <measurement group_id="O5" value="-0.75" spread="1.294"/>
                    <measurement group_id="O6" value="-0.16" spread="0.875"/>
                    <measurement group_id="O7" value="-0.28" spread="0.768"/>
                    <measurement group_id="O8" value="0.27" spread="0.922"/>
                    <measurement group_id="O9" value="0.65" spread="1.176"/>
                    <measurement group_id="O10" value="-0.05" spread="0.689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Hemoglobin</title>
        <description>Measurement of hemoglobin</description>
        <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin</title>
          <description>Measurement of hemoglobin</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.573"/>
                    <measurement group_id="O2" value="-0.62" spread="0.631"/>
                    <measurement group_id="O3" value="-0.50" spread="0.447"/>
                    <measurement group_id="O4" value="-0.30" spread="0.721"/>
                    <measurement group_id="O5" value="0.00" spread="0.410"/>
                    <measurement group_id="O6" value="-0.53" spread="0.599"/>
                    <measurement group_id="O7" value="-0.27" spread="0.683"/>
                    <measurement group_id="O8" value="-1.13" spread="0.723"/>
                    <measurement group_id="O9" value="-1.13" spread="0.314"/>
                    <measurement group_id="O10" value="-0.48" spread="0.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Kidney Function Parameters</title>
        <description>Measurement of blood urea nitrogen (BUN) and creatinine.</description>
        <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Kidney Function Parameters</title>
          <description>Measurement of blood urea nitrogen (BUN) and creatinine.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change of Urea Nitrogen (BUN) Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" spread="3.689"/>
                    <measurement group_id="O2" value="-0.17" spread="2.787"/>
                    <measurement group_id="O3" value="0.83" spread="2.994"/>
                    <measurement group_id="O4" value="-0.17" spread="2.994"/>
                    <measurement group_id="O5" value="-0.33" spread="5.317"/>
                    <measurement group_id="O6" value="2.29" spread="2.289"/>
                    <measurement group_id="O7" value="0.00" spread="4.050"/>
                    <measurement group_id="O8" value="0.83" spread="1.722"/>
                    <measurement group_id="O9" value="-1.67" spread="1.966"/>
                    <measurement group_id="O10" value="-0.33" spread="3.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change of Creatinine Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.099"/>
                    <measurement group_id="O2" value="0.03" spread="0.052"/>
                    <measurement group_id="O3" value="0.02" spread="0.075"/>
                    <measurement group_id="O4" value="0.00" spread="0.089"/>
                    <measurement group_id="O5" value="0.03" spread="0.151"/>
                    <measurement group_id="O6" value="-0.01" spread="0.069"/>
                    <measurement group_id="O7" value="-0.03" spread="0.052"/>
                    <measurement group_id="O8" value="-0.07" spread="0.082"/>
                    <measurement group_id="O9" value="0.10" spread="0.253"/>
                    <measurement group_id="O10" value="-0.02" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Liver Function Parameters</title>
        <description>Measurement of liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]).</description>
        <time_frame>SAD: from baseline to 11 days, MAD: from baseline to 35 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SAD GB002 Placebo QD</title>
            <description>A placebo SAD inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O2">
            <title>SAD GB002 3.75 mg QD</title>
            <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O3">
            <title>SAD GB002 7.5 mg QD</title>
            <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O4">
            <title>SAD GB002 15 mg QD</title>
            <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O5">
            <title>SAD GB002 30 mg QD</title>
            <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O6">
            <title>SAD GB002 48 mg QD</title>
            <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
          </group>
          <group group_id="O7">
            <title>MAD GB002 Placebo BID/TID</title>
            <description>A placebo MAD inhaled either BID or TID to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O8">
            <title>MAD GB002 18 mg BID</title>
            <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O9">
            <title>MAD GB002 24 mg TID</title>
            <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
          <group group_id="O10">
            <title>MAD GB002 48 mg TID</title>
            <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Liver Function Parameters</title>
          <description>Measurement of liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]).</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="3.098"/>
                    <measurement group_id="O2" value="-1.17" spread="5.269"/>
                    <measurement group_id="O3" value="2.50" spread="2.811"/>
                    <measurement group_id="O4" value="1.17" spread="4.750"/>
                    <measurement group_id="O5" value="0.17" spread="2.401"/>
                    <measurement group_id="O6" value="-1.29" spread="2.563"/>
                    <measurement group_id="O7" value="-1.17" spread="3.125"/>
                    <measurement group_id="O8" value="-0.67" spread="3.077"/>
                    <measurement group_id="O9" value="1.17" spread="7.782"/>
                    <measurement group_id="O10" value="-4.17" spread="3.430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="7.203"/>
                    <measurement group_id="O2" value="-0.50" spread="6.025"/>
                    <measurement group_id="O3" value="1.17" spread="1.472"/>
                    <measurement group_id="O4" value="-0.17" spread="2.563"/>
                    <measurement group_id="O5" value="0.67" spread="3.204"/>
                    <measurement group_id="O6" value="-1.14" spread="4.634"/>
                    <measurement group_id="O7" value="-2.83" spread="7.653"/>
                    <measurement group_id="O8" value="-0.50" spread="3.886"/>
                    <measurement group_id="O9" value="3.50" spread="13.096"/>
                    <measurement group_id="O10" value="-2.17" spread="4.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAD: from baseline to day 11, MAD: from baseline to day 35</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SAD GB002 Placebo QD</title>
          <description>A placebo single ascending dose (SAD) inhaled once a day (QD) over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E2">
          <title>SAD GB002 3.75 mg QD</title>
          <description>GB002 SAD 3.75 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E3">
          <title>SAD GB002 7.5 mg QD</title>
          <description>GB002 SAD 7.5 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E4">
          <title>SAD GB002 15 mg QD</title>
          <description>GB002 SAD 15 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E5">
          <title>SAD GB002 30 mg QD</title>
          <description>GB002 SAD 30 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E6">
          <title>SAD GB002 48 mg QD</title>
          <description>GB002 SAD 48 mg inhaled QD over 11 days in healthy volunteers</description>
        </group>
        <group group_id="E7">
          <title>MAD GB002 Placebo BID/TID</title>
          <description>A placebo multiple ascending dose (MAD) inhaled either twice daily (BID) or thrice daily (TID) to match the dosing in the MAD arms over 35 days in healthy volunteers</description>
        </group>
        <group group_id="E8">
          <title>MAD GB002 18 mg BID</title>
          <description>GB002 MAD 18 mg inhaled BID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="E9">
          <title>MAD GB002 24 mg TID</title>
          <description>GB002 MAD 24 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
        <group group_id="E10">
          <title>MAD GB002 48 mg TID</title>
          <description>GB002 MAD 48 mg inhaled TID over 35 days in healthy volunteers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>R. Aranda M.D. / Senior Vice President of Clinical Development</name_or_title>
      <organization>GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.</organization>
      <phone>(858) 684-1300</phone>
      <email>raranda@gossamerbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

